Tharimmune Inc (THAR)

$3.09 +0.19 (6.55%)
Market Cap 22.07M
Revenue (ttm) 0.00
Net Income (ttm) -12.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.22
Volume 303,400
Avg Vol 12,813,074
Day's Range N/A - N/A
Shares Out 7.61M
Stochastic %K 66%
Beta 1.41
Analysts Strong Buy
Price Target $17.00

Company Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets prog...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 270 8260
Address:
1200 Route 22 East, Suite 2000, Bridgewater, United States
WIRE143
WIRE143 Oct. 23 at 7:58 PM
$THAR TH104 as a prophylactic countermeasure for first responders exposed to high-potency opioids has a potential domestic TAM of around $100M if you factor in approximately 2 million US first responders/military personnel x 40/50 a pill, that doesn’t factor in government stock piling. Also Factor in 5 million EU/UK military/first responders, and we have 7 million potential patients and around 300-350m global TAM which excludes Asia. Company only has a 20m market cap and a tiny float of 2m+ shares. FDA allowed company to pursue NDA without any more trials.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 23 at 6:17 PM
$THAR Current Stock Price: $2.82 No options data available.
0 · Reply
Watchbanker
Watchbanker Oct. 21 at 4:14 PM
$THAR Trend Analysis THAR appears to be in a strong bullish trend. Its 200-day moving average is upwards sloping and the MACD histogram is above 0 and rising. Comparative Relative Strength analysis shows that this issue is lagging the S&P 500. As of 11:57 AM ET Tuesday, 10/21/2025
0 · Reply
Makingmillions192
Makingmillions192 Oct. 21 at 2:58 PM
$LEXX Next $THAR type of move coming
0 · Reply
Watchbanker
Watchbanker Oct. 14 at 4:07 PM
$THAR Only way up...No one is selling
0 · Reply
Makingmillions192
Makingmillions192 Oct. 13 at 8:08 PM
$LEXX Also just for reference - after $THAR reported successful phase one results the stock ran like 600%. So lock in before we report phase 1b in Nov / Dec…. 💰
0 · Reply
Ian980
Ian980 Oct. 10 at 7:23 PM
$THAR trumps threatening china on new tariffs crashed everything
1 · Reply
nerowinger
nerowinger Oct. 10 at 6:39 PM
$THAR whole market crashing
0 · Reply
Nye321
Nye321 Oct. 10 at 4:44 PM
$THAR I’m in I feel like we may have another run
0 · Reply
daytraderkns
daytraderkns Oct. 10 at 2:51 PM
$THAR someone explain …. Bought this on a whim got too deep
2 · Reply
Latest News on THAR
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Sep 4, 2025, 8:01 AM EDT - 7 weeks ago

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Aug 20, 2025, 8:00 AM EDT - 2 months ago

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 13, 2025, 8:01 AM EDT - 2 months ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Aug 4, 2025, 8:00 AM EDT - 2 months ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Jul 23, 2025, 10:15 PM EDT - 3 months ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Jun 17, 2025, 8:01 AM EDT - 4 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 30, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 6 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Apr 7, 2025, 8:00 AM EDT - 7 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 24, 2025, 8:00 AM EDT - 7 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025, 7:00 AM EST - 8 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Jan 27, 2025, 8:30 AM EST - 9 months ago

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 16, 2024, 8:00 AM EST - 11 months ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024, 4:15 PM EST - 11 months ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 18, 2024, 8:00 AM EST - 1 year ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024, 8:00 AM EST - 1 year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Nov 4, 2024, 9:00 AM EST - 1 year ago

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 28, 2024, 9:00 AM EDT - 1 year ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 20, 2024, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Feb 5, 2024, 8:30 AM EST - 1 year ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Jan 29, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Dec 11, 2023, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 30, 2023, 4:01 PM EST - 2 years ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 2 years ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 27, 2023, 8:00 AM EST - 2 years ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 17, 2023, 7:00 AM EST - 2 years ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Nov 6, 2023, 5:35 PM EST - 2 years ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 22, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 11, 2023, 11:51 AM EDT - 2 years ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Sep 8, 2023, 2:30 PM EDT - 2 years ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Aug 9, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Jul 10, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Jul 6, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

May 15, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

WIRE143
WIRE143 Oct. 23 at 7:58 PM
$THAR TH104 as a prophylactic countermeasure for first responders exposed to high-potency opioids has a potential domestic TAM of around $100M if you factor in approximately 2 million US first responders/military personnel x 40/50 a pill, that doesn’t factor in government stock piling. Also Factor in 5 million EU/UK military/first responders, and we have 7 million potential patients and around 300-350m global TAM which excludes Asia. Company only has a 20m market cap and a tiny float of 2m+ shares. FDA allowed company to pursue NDA without any more trials.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 23 at 6:17 PM
$THAR Current Stock Price: $2.82 No options data available.
0 · Reply
Watchbanker
Watchbanker Oct. 21 at 4:14 PM
$THAR Trend Analysis THAR appears to be in a strong bullish trend. Its 200-day moving average is upwards sloping and the MACD histogram is above 0 and rising. Comparative Relative Strength analysis shows that this issue is lagging the S&P 500. As of 11:57 AM ET Tuesday, 10/21/2025
0 · Reply
Makingmillions192
Makingmillions192 Oct. 21 at 2:58 PM
$LEXX Next $THAR type of move coming
0 · Reply
Watchbanker
Watchbanker Oct. 14 at 4:07 PM
$THAR Only way up...No one is selling
0 · Reply
Makingmillions192
Makingmillions192 Oct. 13 at 8:08 PM
$LEXX Also just for reference - after $THAR reported successful phase one results the stock ran like 600%. So lock in before we report phase 1b in Nov / Dec…. 💰
0 · Reply
Ian980
Ian980 Oct. 10 at 7:23 PM
$THAR trumps threatening china on new tariffs crashed everything
1 · Reply
nerowinger
nerowinger Oct. 10 at 6:39 PM
$THAR whole market crashing
0 · Reply
Nye321
Nye321 Oct. 10 at 4:44 PM
$THAR I’m in I feel like we may have another run
0 · Reply
daytraderkns
daytraderkns Oct. 10 at 2:51 PM
$THAR someone explain …. Bought this on a whim got too deep
2 · Reply
Baazigar30
Baazigar30 Oct. 8 at 10:28 PM
$THAR I m here so far ..💰💰
1 · Reply
nerowinger
nerowinger Oct. 8 at 7:43 PM
$THAR $INDP $YAAS $PBM money here..
0 · Reply
nerowinger
nerowinger Oct. 8 at 2:32 PM
$THAR need volume here still hold
0 · Reply
Drugtrade
Drugtrade Oct. 8 at 2:29 PM
$THAR adding few on dips.. will they let it stay over $3?
0 · Reply
daytraderkns
daytraderkns Oct. 8 at 1:53 PM
$THAR I’m so deep in this I think this little run is where I take my money
0 · Reply
Watchbanker
Watchbanker Oct. 8 at 1:47 PM
$THAR
0 · Reply
nerowinger
nerowinger Oct. 8 at 1:44 PM
$THAR added
0 · Reply
x1fisher
x1fisher Oct. 8 at 11:10 AM
QTTB most undervalued biotech play on the market. $15 Price target by wells fargo Cash runaway into 2027 with upcoming Phase 2 trial data No warrants and a low float with shorts fully trapped. The squeeze will be historic. $GLTO $XBIO $PHIO $THAR $BURU ww
0 · Reply
Xvool
Xvool Oct. 6 at 6:29 PM
$THAR $3.01 Flagging watch for the break 👁️ also $SPRB $SOPA
0 · Reply
Sw1ngb0t
Sw1ngb0t Oct. 3 at 8:17 PM
$INHD $EEIQ $THAR $VSTD $ISPC
1 · Reply
Sw1ngb0t
Sw1ngb0t Oct. 2 at 9:13 PM
$INHD $EEIQ $VSTD $THAR $IPDN
1 · Reply
x1fisher
x1fisher Oct. 2 at 6:41 PM
MYSE stock new app launch any day now, low float squeeze potential with shorts trapped. Ran to $10 earlier in the year and the CEO IS LOADING $OPEN $MRM $THAR $AMC $GME ww
0 · Reply